Finasteride
Finasteride, Propecia, Proscar (finasteride) is a small molecule pharmaceutical. Finasteride was first approved as Proscar on 1992-06-19. It is used to treat alopecia, hirsutism, prostatic hyperplasia, and prostatic neoplasms in the USA. The pharmaceutical is active against 3-oxo-5-alpha-steroid 4-dehydrogenase 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Finasteride, Propecia, Proscar (discontinued: Finasteride)
CombinationsFinasteride tadalafil (discontinued: Entadfi, Finasteride tadalafil)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dexamethasone sodium phosphate 0.1% / finasteride 0.1% / minoxidil 5% | unapproved drug other | 2019-05-08 |
| dexamethasone sodium phosphate 0.1% / finasteride 0.1% / minoxidil 5% / tretinoin 0.025% | unapproved drug other | 2019-05-08 |
| entadfi | New Drug Application | 2023-01-12 |
| finasteride | ANDA | 2026-03-03 |
| finasteride 0.1% / minoxidil 5% | unapproved drug other | 2019-05-08 |
| finasteride 0.1% / minoxidil 7% | unapproved drug other | 2019-04-24 |
| finasteride 0.1% / minoxidil 7% / tretinoin 0.025% | unapproved drug other | 2019-05-10 |
| johnson foam pro | C200263 | 2025-06-11 |
| nr-11 | Export only | 2017-06-21 |
| propecia | New Drug Application | 2024-10-14 |
Show 1 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AX: Other dermatological preparations in atc
— D11AX10: Finasteride
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04C: Drugs used in benign prostatic hypertrophy
— G04CA: Alpha-adrenoreceptor antagonists, benign prostatic hypertrophy
— G04CA51: Alfuzosin and finasteride
— G04CB: Testosterone-5-alpha reductase inhibitors for benign prostatic hypertrophy
— G04CB01: Finasteride
HCPCS
Code | Description |
|---|---|
| S0138 | Finasteride, 5 mg |
Clinical
Clinical Trials
91 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | 3 | 3 | 7 | 5 | 11 | 29 |
| Alopecia | D000505 | — | L64 | 6 | 6 | 8 | 1 | 2 | 20 |
| Hyperplasia | D006965 | EFO_0000536 | — | 1 | 1 | 4 | 3 | 9 | 18 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | 5 | 4 | 5 | 1 | 2 | 15 |
| Prostatic neoplasms | D011471 | — | C61 | — | 5 | 1 | 2 | 3 | 10 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | — | — | 1 | — | 1 |
| Hyperoxia | D018496 | — | — | — | — | — | 1 | — | 1 |
| Hiv | D006678 | — | O98.7 | — | — | — | 1 | — | 1 |
| Transsexualism | D014189 | — | F64.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polycythemia | D011086 | EFO_0005804 | D75.1 | — | — | 1 | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | 1 | — | — | 1 |
| Prostatic intraepithelial neoplasia | D019048 | — | N42.31 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 10 | 1 | — | — | — | 11 |
| Retinal diseases | D012164 | — | H35.9 | 2 | 3 | — | — | — | 3 |
| Central serous chorioretinopathy | D056833 | — | H35.71 | 2 | 3 | — | — | — | 3 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | 1 | — | — | 2 | 3 |
| Hypogonadism | D007006 | — | E23.0 | 1 | 2 | — | — | — | 3 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | — | 1 | — | — | 1 | 2 |
| Male contraceptive devices | D003275 | — | — | — | 1 | — | — | — | 1 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | 1 | — | — | — | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | — | 1 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | 1 | — | — | — | 1 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | — | 2 |
| Photosensitivity disorders | D010787 | — | L57.1 | 1 | — | — | — | — | 1 |
| Contraception | D003267 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | — | — | — | — | — | — | 1 | 1 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 1 | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 1 | 1 |
| Suicide | D013405 | — | — | — | — | — | — | 1 | 1 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | — | — | — | — | 1 | 1 |
| Urethral obstruction | D014524 | — | — | — | — | — | — | 1 | 1 |
| Urologic diseases | D014570 | — | N39.9 | — | — | — | — | 1 | 1 |
| Prostatic diseases | D011469 | — | N42.9 | — | — | — | — | 1 | 1 |
| Cystocele | D052858 | — | N81.1 | — | — | — | — | 1 | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Finasteride |
| INN | finasteride |
| Description | Finasteride is an aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia. It has a role as an androgen antagonist, an EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor and an antihyperplasia drug. It is an aza-steroid, a 3-oxo steroid and a delta-lactam. It derives from a hydride of a 5alpha-androstane. |
| Classification | Small molecule |
| Drug class | steroids (androgens, anabolics); testosterone reductase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |
Identifiers
| PDB | — |
| CAS-ID | 98319-26-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL710 |
| ChEBI ID | 5062 |
| PubChem CID | 57363 |
| DrugBank | DB01216 |
| UNII ID | 57GNO57U7G (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
AKR1D1
AKR1D1
Organism
Homo sapiens
Gene name
AKR1D1
Gene synonyms
SRD5B1
NCBI Gene ID
Protein name
aldo-keto reductase family 1 member D1
Protein synonyms
3-oxo-5-beta-steroid 4-dehydrogenase, Delta(4)-3-ketosteroid 5-beta-reductase, Delta(4)-3-oxosteroid 5-beta-reductase, steroid-5-beta-reductase, beta polypeptide 1 (3-oxo-5 beta-steroid delta 4-dehydrogenase beta 1)
Uniprot ID
Mouse ortholog
Akr1d1 (208665)
aldo-keto reductase family 1 member D1 (Q8VCX1)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Estimated US medical usage
Finasteride
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,096 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
20,324 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use